XML 35 R24.htm IDEA: XBRL DOCUMENT v3.25.3
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 09, 2025
Jan. 07, 2025
Jan. 06, 2025
Jul. 01, 2024
Jan. 26, 2024
Oct. 06, 2022
Oct. 03, 2022
Mar. 31, 2025
Jan. 31, 2025
Jun. 30, 2012
Sep. 30, 2025
Mar. 31, 2025
 [2]
Jun. 30, 2024
 [3]
Mar. 31, 2024
Sep. 30, 2025
Dec. 31, 2024
Dec. 31, 2023
Jun. 10, 2021
Loss Contingencies [Line Items]                                    
Net sales royalty percenatge                             3.00%      
Gross proceeds from cash fee percentage             7.00%                      
Gross proceeds from management fee percentage             1.00%                      
Stock issued during period, value, new issues                     $ 24,256 [1] $ 25,917 $ 2,022 $ 2,397 [4]        
Litigation settlement amount         $ 2,154                          
Liabilities current                     2,934       $ 2,934 $ 2,460    
Assets current                     80,785       80,785 $ 5,819    
Settlement amount recovery                                 $ 1,100  
Legal expense                                 235  
Non operating loss on legal settlement                                 1,111  
Net proceeds               $ 316                    
Certain Employees [Member]                                    
Loss Contingencies [Line Items]                                    
Accrued bonuses                     535       535      
Device [Member]                                    
Loss Contingencies [Line Items]                                    
Royalties percentage           3.00%                        
Integrated Product [Member]                                    
Loss Contingencies [Line Items]                                    
Royalties percentage           1.50%                        
Common Stock [Member]                                    
Loss Contingencies [Line Items]                                    
Stock issued during period, value, new issues                     $ 127 [1] $ 139 $ 16 $ 17 [4]        
Number of share issued                     12,664,627 [1] 13,891,840 1,566,669 1,685,682 [4]        
At-the-Market Offering Agreement [Member] | Common Stock [Member]                                    
Loss Contingencies [Line Items]                                    
Aggregate offering       $ 4,820                            
Percentage of placement fee       3.00%                            
Number of share issued                 842,606             3,433,880    
Securities Purchase Agreement [Member]                                    
Loss Contingencies [Line Items]                                    
Purchase price of plaintiffs                             $ 6,750      
Securities Purchase Agreement [Member] | Common Stock [Member]                                    
Loss Contingencies [Line Items]                                    
Number of share issued 6,103,289 3,788,550 4,000,001                              
Litigation Settlement [Member]                                    
Loss Contingencies [Line Items]                                    
Payment for litigation settlement         $ 1,100                 $ 1,100        
Restricted common shares issued for legal settlement         1,005,965                          
Liabilities current                                 2,211  
Assets current                                 $ 1,335  
Insurance recovery amount                           $ 1,335        
Litigation Settlement [Member] | Common Stock [Member]                                    
Loss Contingencies [Line Items]                                    
Number of share issued                           1,005,965        
Israeli Innovation Authority [Member] | Minimum [Member]                                    
Loss Contingencies [Line Items]                                    
Net sales royalty percenatge                             3.00%      
Israeli Innovation Authority [Member] | Maximum [Member]                                    
Loss Contingencies [Line Items]                                    
Net sales royalty percenatge                             5.00%      
Israeli Innovation Authority [Member] | CardioSert Ltd [Member]                                    
Loss Contingencies [Line Items]                                    
Repayment of government grants           $ 925                        
Technion Research and Development Foundation Limited [Member] | Minimum [Member]                                    
Loss Contingencies [Line Items]                                    
Net sales royalty percenatge                   1.50%                
Technion Research and Development Foundation Limited [Member] | Maximum [Member]                                    
Loss Contingencies [Line Items]                                    
Net sales royalty percenatge                   3.00%                
H.C. Wainwright & Co. LLC [Member]                                    
Loss Contingencies [Line Items]                                    
Warrant issued, descriptions             The Company has also agreed to issue to Wainwright or its designees preferred investment options upon the closing of such offerings, equal to five (5.0%) percent of the aggregate number of such shares of common stock in such offerings. In addition, upon exercise for cash of any investment options by an investor, the Company has agreed to pay Wainwright a cash fee equal to 7.0% of the gross proceeds from such exercise and to issue to Wainwright or its designees additional preferred investment options equal to five (5.0%) percent of the aggregate number of shares of common stock issued upon such exercise See also Note 4C below.                      
H.C. Wainwright & Co. LLC [Member] | At-the-Market Offering Agreement [Member]                                    
Loss Contingencies [Line Items]                                    
Offering costs                                   $ 10,000
Stock issued during period, value, new issues           $ 8,000                        
2013 Through June 30, 2025 [Member] | Israeli Innovation Authority [Member]                                    
Loss Contingencies [Line Items]                                    
Revenue grants received                             $ 2,154      
[1] Net of issuance costs in the amount of $2,249, of which $153 had not been paid as of September 30, 2025.
[2] Net of issuance costs in the amount of $2,683.
[3] Net of issuance costs in the amount of $328.
[4] Net of issuance costs in the amount of $333.